• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB 1.86% $1.19

MESOBLAST LIMITED - Announcements

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk

MSB Mesoblast Newsletter - Chronic Low Back Pain27/09/19 download Created with Sketch. 575.08KB
MSB Analyst Call Presentation10/09/19 download Created with Sketch. 1.7MB
MSB Analyst Call Details10/09/19 download Created with Sketch. 83.18KB
MSB Grunenthal and MSB Enter Strategic Partnership for Back PainPRICE SENSITIVE10/09/19 download Created with Sketch. 127.73KB
MSB Mesoblast Reports on Annual ResultsPRICE SENSITIVE30/08/19 download Created with Sketch. 243.33KB
MSB Annual Financial Results Presentation30/08/19 download Created with Sketch. 4.48MB
MSB Preliminary Final Report including Appendix 4EPRICE SENSITIVE30/08/19 download Created with Sketch. 3.68MB
MSB FDA Guidance on Clinical Pathway for LVAD Market ApplicationPRICE SENSITIVE27/08/19 download Created with Sketch. 108.18KB
MSB Investigator-Initiated Trial Planned for Chronic GVHD14/08/19 download Created with Sketch. 73.45KB
MSB Mesoblast Appoints Leading Pharma Industry Executive as CMO12/08/19 download Created with Sketch. 72.69KB
MSB Appendix 4C - Quarterly, Strong Commercialization RevenuesPRICE SENSITIVE31/07/19 download Created with Sketch. 198.68KB
MSB Circulation Research Highlights MSB Heart Failure TherapyPRICE SENSITIVE25/07/19 download Created with Sketch. 125.8KB
MSB Newsletter - Interview with GvHD Key Opinion Leader15/07/19 download Created with Sketch. 931.81KB
MSB Change in substantial holding12/07/19 download Created with Sketch. 77.12KB
MSB Appendix 3B11/07/19 download Created with Sketch. 113.03KB
MSB Release of Shares from Voluntary Escrow26/06/19 download Created with Sketch. 86.12KB
MSB FDA Grants Revascor Orphan Drug For End Stage CHF With LVADsPRICE SENSITIVE24/06/19 download Created with Sketch. 134.93KB
MSB High Economic Burden In Steroid-Refractory aGVHD18/06/19 download Created with Sketch. 94.6KB
MSB MSB to Host Virtual Symposium with KOL on GvHD17/06/19 download Created with Sketch. 92.26KB
MSB MSB Expands JCR Partnership To Brain Disease In NewbornsPRICE SENSITIVE11/06/19 download Created with Sketch. 94.26KB
MSB MSB Provides Q3 Financial Results and Operational HighlightsPRICE SENSITIVE31/05/19 download Created with Sketch. 184.53KB
MSB Third Quarter Results Presentation31/05/19 download Created with Sketch. 3.41MB
MSB Third Quarter Financial Results on Form 6-KPRICE SENSITIVE31/05/19 download Created with Sketch. 536.5KB
MSB MSB Financial Results Webcast Timing30/05/19 download Created with Sketch. 70.43KB
MSB Mesoblast Initiates Rolling Submission of BLA for GvHDPRICE SENSITIVE30/05/19 download Created with Sketch. 94.56KB
MSB Mesoblast Keynote Presentations at ISCT Annual Meeting23/05/19 download Created with Sketch. 250.96KB
MSB Mesoblast to Present at RBC Global Healthcare Conference17/05/19 download Created with Sketch. 65KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE30/04/19 download Created with Sketch. 134.84KB
MSB FDA Agrees to Rolling Review of Mesoblast BLA Submission16/04/19 download Created with Sketch. 121.86KB
MSB Final Director's Interest Notice05/04/19 download Created with Sketch. 60.47KB
MSB Presentation at Upcoming Global Life Science Conference05/04/19 download Created with Sketch. 80.76KB
MSB MoU for Confirmatory Trial for GI Bleeding in LVAD PatientsPRICE SENSITIVE27/03/19 download Created with Sketch. 107.1KB
MSB MSB Licensee Files For Skin Disease Marketing ApprovalPRICE SENSITIVE25/03/19 download Created with Sketch. 91.43KB
MSB Joseph R. Swedish Appointed Mesoblast Chairman22/03/19 download Created with Sketch. 89.81KB
MSB Change in substantial holding18/03/19 download Created with Sketch. 187.71KB
MSB Upcoming U.S. Investor Conferences13/03/19 download Created with Sketch. 96.33KB
MSB Mesoblast Provides Half Year Results and Corporate UpdatePRICE SENSITIVE21/02/19 download Created with Sketch. 187.06KB
MSB Half Year Financial Results Presentation21/02/19 download Created with Sketch. 1.35MB
MSB Half Year Report and Accounts (including Appendix 4D)PRICE SENSITIVE21/02/19 download Created with Sketch. 693.79KB
MSB Final Patient Dosed in Mesoblast P3 Heart Failure Trial19/02/19 download Created with Sketch. 87.78KB
MSB Mesoblast Newsletter on Advanced and End-Stage Heart Failure19/02/19 download Created with Sketch. 237.48KB
MSB Change in substantial holding11/02/19 download Created with Sketch. 188.74KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/01/19 download Created with Sketch. 133.52KB
MSB MSB Draws US$15 Million From Existing FacilityPRICE SENSITIVE14/01/19 download Created with Sketch. 122.84KB
MSB MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase08/01/19 download Created with Sketch. 213.69KB
MSB Change of Director's Interest Notices08/01/19 download Created with Sketch. 183.24KB
MSB P3 Trial of MSB's Cell Therapy in CHF Completes RecruitmentPRICE SENSITIVE07/01/19 download Created with Sketch. 88.48KB
MSB Cleansing notice and Appendix 3B07/01/19 download Created with Sketch. 264.09KB
MSB Mesoblast Corporate Review28/12/18 download Created with Sketch. 135.21KB
MSB Mesoblast to Present at 2019 Biotech Showcase in USA24/12/18 download Created with Sketch. 71.28KB
MSB MSB Makes Executive Appointment To Drive Commercialization19/12/18 download Created with Sketch. 103.05KB
MSB Meetings Held With FDA Support MSB's Planned GVHD Filing13/12/18 download Created with Sketch. 90.54KB
MSB Response to ASX queryPRICE SENSITIVE05/12/18 download Created with Sketch. 421.44KB
MSB Results of Meeting30/11/18 download Created with Sketch. 177.79KB
MSB Presentation to 2018 Annual General Meeting30/11/18 download Created with Sketch. 1.37MB
MSB Chairman's Address to Shareholders30/11/18 download Created with Sketch. 75.97KB
MSB Tasly and MSB Initiate Activities For MPC-150-IM In China26/11/18 download Created with Sketch. 344.04KB
MSB MSB Provides Q1 Financial Results and Operational HighlightsPRICE SENSITIVE16/11/18 download Created with Sketch. 304.15KB
MSB First Quarter Results Presentation16/11/18 download Created with Sketch. 2.76MB
MSB First Quarter Financial Results on Form 6-KPRICE SENSITIVE16/11/18 download Created with Sketch. 468.25KB
MSB LVAD Results Webcast PresentationPRICE SENSITIVE13/11/18 download Created with Sketch. 1.58MB
MSB LVAD Trial Results Provide Potential Regulatory PathwayPRICE SENSITIVE12/11/18 download Created with Sketch. 153.14KB
MSB Pause in TradingPRICE SENSITIVE12/11/18 download Created with Sketch. 115.8KB
MSB MSB To Host Webcast For Heart Failure Results At AHA09/11/18 download Created with Sketch. 67.84KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/10/18 download Created with Sketch. 124.88KB
MSB Annual Report to shareholders30/10/18 download Created with Sketch. 2.41MB
MSB Notice of General Meeting/Proxy Form30/10/18 download Created with Sketch. 302.32KB
MSB Appendix 4G and Corporate Governance Statement30/10/18 download Created with Sketch. 183.17KB
MSB GVHD and CHF Updates to Emerging Leaders Conference25/10/18 download Created with Sketch. 2.48MB
MSB MSB Expands Partnership With JCR For Skin DiseasePRICE SENSITIVE24/10/18 download Created with Sketch. 92.16KB
MSB Change in substantial holding16/10/18 download Created with Sketch. 260.5KB
MSB Completion of Tasly Transaction, and Appendix 3BPRICE SENSITIVE12/10/18 download Created with Sketch. 302.01KB
MSB Release of shares from voluntary escrow11/10/18 download Created with Sketch. 85.28KB
MSB End-Stage HF Results Selected For AHA Scientific Sessions02/10/18 download Created with Sketch. 87.78KB
MSB Mesoblast Cardiac Cell Therapy In Children25/09/18 download Created with Sketch. 95.15KB
MSB Day 180 Survival Outcomes In aGvHD Phase 3 TrialPRICE SENSITIVE20/09/18 download Created with Sketch. 97.85KB
MSB Tasly Receives Approvals For Transaction With MSBPRICE SENSITIVE17/09/18 download Created with Sketch. 71.22KB
MSB Mesoblast Reports on Annual and Fourth Quarter ResultsPRICE SENSITIVE30/08/18 download Created with Sketch. 219.59KB
MSB Annual Financial Results Presentation30/08/18 download Created with Sketch. 2.21MB
MSB Preliminary Final Report including Appendix 4EPRICE SENSITIVE30/08/18 download Created with Sketch. 1.6MB
MSB UPDATE ON TASLY TRANSACTIONPRICE SENSITIVE29/08/18 download Created with Sketch. 89.39KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/07/18 download Created with Sketch. 117.52KB
MSB Initial Director's Interest Notice18/07/18 download Created with Sketch. 62.49KB
MSB MSB Enters Into Cardiovascular Alliance For China With TaslyPRICE SENSITIVE17/07/18 download Created with Sketch. 80.49KB
MSB Director Appointment/Resignation11/07/18 download Created with Sketch. 89.85KB
MSB Appendix 3B10/07/18 download Created with Sketch. 184.33KB
MSB MSB Enters Into US$50M Financing With NovaQuest CapitalPRICE SENSITIVE02/07/18 download Created with Sketch. 80.37KB
MSB Initial and Final Directors' Interest Notices25/06/18 download Created with Sketch. 140.45KB
MSB ISSCR Presentation on P3 GVHD Trial Survival Benefits22/06/18 download Created with Sketch. 1.77MB
MSB Key Day 100 Survival Results In P3 GvHD TrialPRICE SENSITIVE21/06/18 download Created with Sketch. 76.22KB
MSB Director Appointment/Resignation19/06/18 download Created with Sketch. 74.62KB
MSB MSB Provides Q3 Financial Results and Operational Highlights31/05/18 download Created with Sketch. 212.11KB
MSB Mesoblast Appoints New Chief Financial Officer31/05/18 download Created with Sketch. 74.97KB
MSB Third Quarter Results Presentation31/05/18 download Created with Sketch. 965.73KB
MSB Third Quarter Financial Results on Form 6-KPRICE SENSITIVE31/05/18 download Created with Sketch. 515.82KB
MSB Partnership For Allogeneic Cell-based Cancer ImmunotherapiesPRICE SENSITIVE29/05/18 download Created with Sketch. 77.36KB
MSB Cleansing notice and Appendix 3B15/05/18 download Created with Sketch. 233.86KB
MSB MSB P3 Results For GVHD Presented At ISCT Meeting08/05/18 download Created with Sketch. 95.17KB
MSB MSB Cell Therapies Featured At Vatican Healthcare Conference01/05/18 download Created with Sketch. 73KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE30/04/18 download Created with Sketch. 114.44KB
MSB Mesoblast Newsletter - Chronic Low Back Pain
27/09/19 download Created with Sketch. 575.08KB
MSB Analyst Call Presentation
10/09/19 download Created with Sketch. 1.7MB
MSB Analyst Call Details
10/09/19 download Created with Sketch. 83.18KB
MSB Grunenthal and MSB Enter Strategic Partnership for Back Pain
10/09/19PRICE SENSITIVE download Created with Sketch. 127.73KB
MSB Mesoblast Reports on Annual Results
30/08/19PRICE SENSITIVE download Created with Sketch. 243.33KB
MSB Annual Financial Results Presentation
30/08/19 download Created with Sketch. 4.48MB
MSB Preliminary Final Report including Appendix 4E
30/08/19PRICE SENSITIVE download Created with Sketch. 3.68MB
MSB FDA Guidance on Clinical Pathway for LVAD Market Application
27/08/19PRICE SENSITIVE download Created with Sketch. 108.18KB
MSB Investigator-Initiated Trial Planned for Chronic GVHD
14/08/19 download Created with Sketch. 73.45KB
MSB Mesoblast Appoints Leading Pharma Industry Executive as CMO
12/08/19 download Created with Sketch. 72.69KB
MSB Appendix 4C - Quarterly, Strong Commercialization Revenues
31/07/19PRICE SENSITIVE download Created with Sketch. 198.68KB
MSB Circulation Research Highlights MSB Heart Failure Therapy
25/07/19PRICE SENSITIVE download Created with Sketch. 125.8KB
MSB Newsletter - Interview with GvHD Key Opinion Leader
15/07/19 download Created with Sketch. 931.81KB
MSB Change in substantial holding
12/07/19 download Created with Sketch. 77.12KB
MSB Appendix 3B
11/07/19 download Created with Sketch. 113.03KB
MSB Release of Shares from Voluntary Escrow
26/06/19 download Created with Sketch. 86.12KB
MSB FDA Grants Revascor Orphan Drug For End Stage CHF With LVADs
24/06/19PRICE SENSITIVE download Created with Sketch. 134.93KB
MSB High Economic Burden In Steroid-Refractory aGVHD
18/06/19 download Created with Sketch. 94.6KB
MSB MSB to Host Virtual Symposium with KOL on GvHD
17/06/19 download Created with Sketch. 92.26KB
MSB MSB Expands JCR Partnership To Brain Disease In Newborns
11/06/19PRICE SENSITIVE download Created with Sketch. 94.26KB
MSB MSB Provides Q3 Financial Results and Operational Highlights
31/05/19PRICE SENSITIVE download Created with Sketch. 184.53KB
MSB Third Quarter Results Presentation
31/05/19 download Created with Sketch. 3.41MB
MSB Third Quarter Financial Results on Form 6-K
31/05/19PRICE SENSITIVE download Created with Sketch. 536.5KB
MSB MSB Financial Results Webcast Timing
30/05/19 download Created with Sketch. 70.43KB
MSB Mesoblast Initiates Rolling Submission of BLA for GvHD
30/05/19PRICE SENSITIVE download Created with Sketch. 94.56KB
MSB Mesoblast Keynote Presentations at ISCT Annual Meeting
23/05/19 download Created with Sketch. 250.96KB
MSB Mesoblast to Present at RBC Global Healthcare Conference
17/05/19 download Created with Sketch. 65KB
MSB Appendix 4C - quarterly
30/04/19PRICE SENSITIVE download Created with Sketch. 134.84KB
MSB FDA Agrees to Rolling Review of Mesoblast BLA Submission
16/04/19 download Created with Sketch. 121.86KB
MSB Final Director's Interest Notice
05/04/19 download Created with Sketch. 60.47KB
MSB Presentation at Upcoming Global Life Science Conference
05/04/19 download Created with Sketch. 80.76KB
MSB MoU for Confirmatory Trial for GI Bleeding in LVAD Patients
27/03/19PRICE SENSITIVE download Created with Sketch. 107.1KB
MSB MSB Licensee Files For Skin Disease Marketing Approval
25/03/19PRICE SENSITIVE download Created with Sketch. 91.43KB
MSB Joseph R. Swedish Appointed Mesoblast Chairman
22/03/19 download Created with Sketch. 89.81KB
MSB Change in substantial holding
18/03/19 download Created with Sketch. 187.71KB
MSB Upcoming U.S. Investor Conferences
13/03/19 download Created with Sketch. 96.33KB
MSB Mesoblast Provides Half Year Results and Corporate Update
21/02/19PRICE SENSITIVE download Created with Sketch. 187.06KB
MSB Half Year Financial Results Presentation
21/02/19 download Created with Sketch. 1.35MB
MSB Half Year Report and Accounts (including Appendix 4D)
21/02/19PRICE SENSITIVE download Created with Sketch. 693.79KB
MSB Final Patient Dosed in Mesoblast P3 Heart Failure Trial
19/02/19 download Created with Sketch. 87.78KB
MSB Mesoblast Newsletter on Advanced and End-Stage Heart Failure
19/02/19 download Created with Sketch. 237.48KB
MSB Change in substantial holding
11/02/19 download Created with Sketch. 188.74KB
MSB Appendix 4C - quarterly
31/01/19PRICE SENSITIVE download Created with Sketch. 133.52KB
MSB MSB Draws US$15 Million From Existing Facility
14/01/19PRICE SENSITIVE download Created with Sketch. 122.84KB
MSB MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase
08/01/19 download Created with Sketch. 213.69KB
MSB Change of Director's Interest Notices
08/01/19 download Created with Sketch. 183.24KB
MSB P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment
07/01/19PRICE SENSITIVE download Created with Sketch. 88.48KB
MSB Cleansing notice and Appendix 3B
07/01/19 download Created with Sketch. 264.09KB
MSB Mesoblast Corporate Review
28/12/18 download Created with Sketch. 135.21KB
MSB Mesoblast to Present at 2019 Biotech Showcase in USA
24/12/18 download Created with Sketch. 71.28KB
MSB MSB Makes Executive Appointment To Drive Commercialization
19/12/18 download Created with Sketch. 103.05KB
MSB Meetings Held With FDA Support MSB's Planned GVHD Filing
13/12/18 download Created with Sketch. 90.54KB
MSB Response to ASX query
05/12/18PRICE SENSITIVE download Created with Sketch. 421.44KB
MSB Results of Meeting
30/11/18 download Created with Sketch. 177.79KB
MSB Presentation to 2018 Annual General Meeting
30/11/18 download Created with Sketch. 1.37MB
MSB Chairman's Address to Shareholders
30/11/18 download Created with Sketch. 75.97KB
MSB Tasly and MSB Initiate Activities For MPC-150-IM In China
26/11/18 download Created with Sketch. 344.04KB
MSB MSB Provides Q1 Financial Results and Operational Highlights
16/11/18PRICE SENSITIVE download Created with Sketch. 304.15KB
MSB First Quarter Results Presentation
16/11/18 download Created with Sketch. 2.76MB
MSB First Quarter Financial Results on Form 6-K
16/11/18PRICE SENSITIVE download Created with Sketch. 468.25KB
MSB LVAD Results Webcast Presentation
13/11/18PRICE SENSITIVE download Created with Sketch. 1.58MB
MSB LVAD Trial Results Provide Potential Regulatory Pathway
12/11/18PRICE SENSITIVE download Created with Sketch. 153.14KB
MSB Pause in Trading
12/11/18PRICE SENSITIVE download Created with Sketch. 115.8KB
MSB MSB To Host Webcast For Heart Failure Results At AHA
09/11/18 download Created with Sketch. 67.84KB
MSB Appendix 4C - quarterly
31/10/18PRICE SENSITIVE download Created with Sketch. 124.88KB
MSB Annual Report to shareholders
30/10/18 download Created with Sketch. 2.41MB
MSB Notice of General Meeting/Proxy Form
30/10/18 download Created with Sketch. 302.32KB
MSB Appendix 4G and Corporate Governance Statement
30/10/18 download Created with Sketch. 183.17KB
MSB GVHD and CHF Updates to Emerging Leaders Conference
25/10/18 download Created with Sketch. 2.48MB
MSB MSB Expands Partnership With JCR For Skin Disease
24/10/18PRICE SENSITIVE download Created with Sketch. 92.16KB
MSB Change in substantial holding
16/10/18 download Created with Sketch. 260.5KB
MSB Completion of Tasly Transaction, and Appendix 3B
12/10/18PRICE SENSITIVE download Created with Sketch. 302.01KB
MSB Release of shares from voluntary escrow
11/10/18 download Created with Sketch. 85.28KB
MSB End-Stage HF Results Selected For AHA Scientific Sessions
02/10/18 download Created with Sketch. 87.78KB
MSB Mesoblast Cardiac Cell Therapy In Children
25/09/18 download Created with Sketch. 95.15KB
MSB Day 180 Survival Outcomes In aGvHD Phase 3 Trial
20/09/18PRICE SENSITIVE download Created with Sketch. 97.85KB
MSB Tasly Receives Approvals For Transaction With MSB
17/09/18PRICE SENSITIVE download Created with Sketch. 71.22KB
MSB Mesoblast Reports on Annual and Fourth Quarter Results
30/08/18PRICE SENSITIVE download Created with Sketch. 219.59KB
MSB Annual Financial Results Presentation
30/08/18 download Created with Sketch. 2.21MB
MSB Preliminary Final Report including Appendix 4E
30/08/18PRICE SENSITIVE download Created with Sketch. 1.6MB
MSB UPDATE ON TASLY TRANSACTION
29/08/18PRICE SENSITIVE download Created with Sketch. 89.39KB
MSB Appendix 4C - quarterly
31/07/18PRICE SENSITIVE download Created with Sketch. 117.52KB
MSB Initial Director's Interest Notice
18/07/18 download Created with Sketch. 62.49KB
MSB MSB Enters Into Cardiovascular Alliance For China With Tasly
17/07/18PRICE SENSITIVE download Created with Sketch. 80.49KB
MSB Director Appointment/Resignation
11/07/18 download Created with Sketch. 89.85KB
MSB Appendix 3B
10/07/18 download Created with Sketch. 184.33KB
MSB MSB Enters Into US$50M Financing With NovaQuest Capital
02/07/18PRICE SENSITIVE download Created with Sketch. 80.37KB
MSB Initial and Final Directors' Interest Notices
25/06/18 download Created with Sketch. 140.45KB
MSB ISSCR Presentation on P3 GVHD Trial Survival Benefits
22/06/18 download Created with Sketch. 1.77MB
MSB Key Day 100 Survival Results In P3 GvHD Trial
21/06/18PRICE SENSITIVE download Created with Sketch. 76.22KB
MSB Director Appointment/Resignation
19/06/18 download Created with Sketch. 74.62KB
MSB MSB Provides Q3 Financial Results and Operational Highlights
31/05/18 download Created with Sketch. 212.11KB
MSB Mesoblast Appoints New Chief Financial Officer
31/05/18 download Created with Sketch. 74.97KB
MSB Third Quarter Results Presentation
31/05/18 download Created with Sketch. 965.73KB
MSB Third Quarter Financial Results on Form 6-K
31/05/18PRICE SENSITIVE download Created with Sketch. 515.82KB
MSB Partnership For Allogeneic Cell-based Cancer Immunotherapies
29/05/18PRICE SENSITIVE download Created with Sketch. 77.36KB
MSB Cleansing notice and Appendix 3B
15/05/18 download Created with Sketch. 233.86KB
MSB MSB P3 Results For GVHD Presented At ISCT Meeting
08/05/18 download Created with Sketch. 95.17KB
MSB MSB Cell Therapies Featured At Vatican Healthcare Conference
01/05/18 download Created with Sketch. 73KB
MSB Appendix 4C - quarterly
30/04/18PRICE SENSITIVE download Created with Sketch. 114.44KB
(20min delay)
Last
$1.19
Change
-0.023(1.86%)
Mkt cap ! $1.364B
Open High Low Value Volume
$1.21 $1.21 $1.18 $804.4K 674.6K

Buyers (Bids)

No. Vol. Price($)
10 111404 $1.19
 

Sellers (Offers)

Price($) Vol. No.
$1.19 13769 7
View Market Depth
Last trade - 11.07am 02/10/2024 (20 minute delay) ?
Last
$1.20
  Change
-0.023 ( 0.90 %)
Open High Low Volume
$1.21 $1.21 $1.19 114021
Last updated 11.27am 02/10/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.